Advertisement

Osteoporosis International

, Volume 29, Issue 2, pp 315–322 | Cite as

Osteoporosis and bone mineral density in patients with Wilson’s disease: a systematic review and meta-analysis

  • J. Chenbhanich
  • C. Thongprayoon
  • A. Atsawarungruangkit
  • T. Phupitakphol
  • W. Cheungpasitporn
Review

Abstract

This systematic review aims to assess the occurrence and risks of osteopenia and osteoporosis in patientswith Wilson's disease (WD). A literature search was conducted utilizing EMBASE and MEDLINE frominception through April 2017. Studies assessing the occurrence or risk of osteopenia and/or osteoporosis inWD patients were included. Effect estimates from the individual study were extracted and combined usingrandom-effect, generic inverse variance method of DerSimonian and Laird. Of 754 studies, four studies with283 WD patients met the eligibility criteria and were included in the data analysis. The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5% (95% confidence interval [CI]: 14.8%-65.7%) and 27.7% (95%CI: 8.6%-60.9%), respectively. When meta-analysis was limited only to adults, the estimated prevalence rates of osteopenia, osteoporosis, and vertebral fracture were 50.0% (95%CI: 42.0%-58.0%), 17.6% (95%CI: 6.7%-38.6%) and 8.01% (95%CI: 4.05%-15.2%), respectively. Meta-regressionshowed significant impacts of age (negative correlation; P=0.002) and male status (positive correlation;P < 0.001) on the prevalence of osteoporosis. The data on risks of osteopenia and osteoporosis in WDpatients were limited. We suggests that there are potential associations of WD with osteopenia and/orosteoporosis. Also, young age and male status are correlated with the higher prevalence of osteoporosis inWD patients.

Keywords

Bone mineral density Dual-energy X-ray absorptiometry Hepatolenticular degeneration Osteopenia Osteoporosis Wilson’s disease 

Notes

Acknowledgements

We would like to express our gratitude to Marian MacMaster and Joan Yanicke, our lovely librarians at the Medical Library, Metrowest Medical Center, for helping us retrieve all the relevant articles.

Compliance with ethical standards

Conflicts of interest

None.

Supplementary material

198_2017_4295_MOESM1_ESM.docx (59 kb)
ESM 1 (DOCX 59kb)
198_2017_4295_MOESM2_ESM.docx (24 kb)
ESM 2 (DOCX 24kb)
198_2017_4295_MOESM3_ESM.docx (71 kb)
Supplementary Table 1 (DOCX 71kb)

References

  1. 1.
    Bandmann O, Weiss KH, Kaler SG (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol 14:103–113CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Coffey AJ, Durkie M, Hague S et al (2013) A genetic study of Wilson’s disease in the United Kingdom. Brain 136:1476–1487CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Quemeneur AS, Trocello JM, Ea HK, Woimant F, Liote F (2011) Miscellaneous non-inflammatory musculoskeletal conditions. Musculoskeletal conditions associated with Wilson’s disease. Best Pract Res Clin Rheumatol 25:627–636CrossRefPubMedGoogle Scholar
  4. 4.
    Aggarwal A, Aggarwal N, Nagral A, Jankharia G, Bhatt M (2009) A novel global assessment scale for Wilson’s disease (GAS for WD). Mov Disord 24:509–518CrossRefPubMedGoogle Scholar
  5. 5.
    Yu H, Xie JJ, Chen YC, Dong QY, Dong Y, Ni W, Wu ZY (2017) Clinical features and outcome in patients with osseomuscular type of Wilson’s disease. BMC Neurol 17:34CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261–268PubMedGoogle Scholar
  7. 7.
    Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474–1482CrossRefPubMedGoogle Scholar
  8. 8.
    Cetinkaya A, Ozen H, Yuce A, Saltik-Temizel IN, Demir H, Gurakan F (2014) Bone mineralization in children with Wilson’s disease. Indian J Gastroenterol 33:427–431CrossRefPubMedGoogle Scholar
  9. 9.
    Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F (2002) Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17:1961–1967CrossRefPubMedGoogle Scholar
  10. 10.
    Selimoglu MA, Ertekin V, Doneray H, Yildirim M (2008) Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. J Clin Gastroenterol 42:194–198CrossRefPubMedGoogle Scholar
  11. 11.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr, International Society for Clinical D (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655CrossRefPubMedGoogle Scholar
  13. 13.
    Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMedGoogle Scholar
  14. 14.
    DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114CrossRefPubMedGoogle Scholar
  15. 15.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kelley GA, Kelley KS (2012) Statistical models for meta-analysis: a brief tutorial. World J Methodol 2:27–32CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872CrossRefPubMedGoogle Scholar
  18. 18.
    Quemeneur AS, Trocello JM, Ea HK, Ostertag A, Leyendecker A, Duclos-Vallee JC, de Vernejoul MC, Woimant F, Liote F (2014) Bone status and fractures in 85 adults with Wilson’s disease. Osteoporos Int 25:2573–2580CrossRefPubMedGoogle Scholar
  19. 19.
    Weiss KH, Van de Moortele M, Gotthardt DN et al (2015) Bone demineralisation in a large cohort of Wilson disease patients. J Inherit Metab Dis 38:949–956CrossRefPubMedGoogle Scholar
  20. 20.
    Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version5.1.0. The Cochrane Collaboration. Available from www.cochranehandbook.orgorg.
  21. 21.
    Finby N, Bearn AG (1958) Roentgenographic abnormalities of the skeletal system in Wilson’s disease (hepatolenticular degeneration). Am J Roentgenol Radium Therapy, Nucl Med 79:603–611Google Scholar
  22. 22.
    Shin JJ, Lee JP, Rah JH (2015) Fracture in a young male patient leading to the diagnosis of Wilson’s disease: a case report. J Bone Metab 22:33–37CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nakchbandi IA (2014) Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol 20:9427–9438PubMedPubMedCentralGoogle Scholar
  24. 24.
    Xie YZ, Zhang XZ, XH X, Zhang ZX, Feng YK (1985) Radiologic study of 42 cases of Wilson disease. Skelet Radiol 13:114–119CrossRefGoogle Scholar
  25. 25.
    Subrahmanyam DK, Vadivelan M, Giridharan S, Balamurugan N (2014) Wilson’s disease—a rare cause of renal tubular acidosis with metabolic bone disease. Indian J Nephrol 24:171–174CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Litwin T, Gromadzka G, Czlonkowska A (2012) Gender differences in Wilson’s disease. J Neurol Sci 312:31–35CrossRefPubMedGoogle Scholar
  27. 27.
    Huang X, Xu Y, Partridge NC (2013) Dancing with sex hormones, could iron contribute to the gender difference in osteoporosis? Bone 55:458–460CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kim BJ, Ahn SH, Bae SJ, Kim EH, Lee SH, Kim HK, Choe JW, Koh JM, Kim GS (2012) Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J Bone Miner Res 27:2279–2290CrossRefPubMedGoogle Scholar
  29. 29.
    Jeney V (2017) Clinical impact and cellular mechanisms of iron overload-associated bone loss. Front Pharmacol 8:77CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hafkemeyer P, Schupp M, Storch M, Gerok W, Haussinger D (1994) Excessive iron storage in a patient with Wilson’s disease. Clin Investig 72:134–136CrossRefPubMedGoogle Scholar
  31. 31.
    Walshe JM, Cox DW (1998) Effect of treatment of Wilson’s disease on natural history of haemochromatosis. Lancet 352:112–113CrossRefPubMedGoogle Scholar
  32. 32.
    Shiono Y, Wakusawa S, Hayashi H, Takikawa T, Yano M, Okada T, Mabuchi H, Kono S, Miyajima H (2001) Iron accumulation in the liver of male patients with Wilson’s disease. Am J Gastroenterol 96:3147–3151CrossRefPubMedGoogle Scholar
  33. 33.
    Pfeiffenberger J, Gotthardt DN, Herrmann T, Seessle J, Merle U, Schirmacher P, Stremmel W, Weiss KH (2012) Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int 32:165–170CrossRefPubMedGoogle Scholar
  34. 34.
    Aksoy M, Camli N, Dincol K, Erdem S, Akgun T (1972) Osseous changes in Wilson’s disease. A radiologic study of nine patients. Radiology 102:505–509CrossRefPubMedGoogle Scholar
  35. 35.
    Ferenci P, Czlonkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W (2007) Late-onset Wilson’s disease. Gastroenterology 132:1294–1298CrossRefPubMedGoogle Scholar
  36. 36.
    Gafni RI, Baron J (2004) Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 144:253–257CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Authors and Affiliations

  1. 1.Department of Internal MedicineMetrowest Medical CenterFraminghamUSA
  2. 2.Department of Internal MedicineBassett Medical CenterCooperstownUSA
  3. 3.Division of Nephrology and Hypertension, Department of MedicineMayo ClinicRochesterUSA
  4. 4.Division of Nephrology, Department of Internal MedicineUniversity of Mississippi Medical CenterJacksonUSA

Personalised recommendations